2Disse B, Reichal R, Speck G, et al. Ba679BR, a novel anticholinergic bronchodilator: preclinical and clinical aspects [J]. Life Sci, 1993, 52(5-6): 537-544.
3Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease [J]. Life Sci, 1999, 64(6-7): 457-464.
4Takahashi T, Belvisi MG, Patet H, et al. Effect of Ba679BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmisson in guinea pig and human airways [J]. Am J Respir Crit Care Med, 1994, 150(6 Pt 1): 1640-1645.
5Buhling F, Lieder N, Kuhlmann VC et al. Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro [J]. Respir Med, 2007, 101(11): 2186- 2194.
6Koyama S, Sato E, Nomuna H, et al. Acetylcholine and substance P stimulate bronchial epithelial cells release eosinophil chemotactic activity [J]. J Appl Physiol, 1998, 84(5): 1528-1534.
7Sato E, Koyama S, Okubo Y, et al. Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity [J]. Am J Physiol, 1998, 274(6 Pt 1): L970-L979.
8Koyama S, Rennard SI, Robbins RA. Acetylcholine stimulate bronchial epithelial cells to release neutrophil and monocyte chemotactic activity [J]. Am J Physiol, 1992, 262(4 Pt 1): L466-L471.
9Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation [J]. Eur Respir J, 2007, 29(3): 527-534.
10Powrie DJ, Wilkinson TMA, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD [J]. Eur Respir J, 2007, 30(3): 472- 478.
